AXL is expressed in many types of cancer and promotes cancer cell survival, metastasis and drug resistance. Here, we focus on identifying modulators that regulate AXL at the mRNA level. We have previously observed that the AXL promoter activity is inversely correlated with the AXL expression levels, suggesting that post-transcriptional mechanisms exist that down-regulate the expression of AXL mRNA. Here we show that the RNA binding protein PTBP1 (polypyrimidine tract-binding protein) directly targets the 5′-UTR of AXL mRNA in vitro and in vivo. Moreover, we also demonstrate that PTBP1, but not PTBP2, inhibits the expression of AXL mRNA and the RNA recognition motif 1 (RRM1) of PTBP1 is crucial for this interaction. To clarify how PTBP1 regulates AXL expression at the mRNA level, we found that, while the transcription rate of AXL was not significantly different, PTBP1 decreased the stability of AXL mRNA. In addition, over-expression of AXL may counteract the PTBP1-mediated apoptosis. Knock-down of PTBP1 expression could enhance tumor growth in animal models. Finally, PTBP1 was found to be negatively correlated with AXL expression in lung tumor tissues in Oncomine datasets and in tissue micro-array (TMA) analysis. In conclusion, we have identified a molecular mechanism of AXL expression regulation by PTBP1 through controlling the AXL mRNA stability. These findings may represent new thoughts alternative to current approaches that directly inhibit AXL signaling and may eventually help to develop novel therapeutics to avoid cancer metastasis and drug resistance.
Results
AXL expression positively correlates with the AXL 5′-UTR reporter activity but not the 3′-UTR reporter activity. Since AXL plays important roles in cancer progression, it is therefore crucial to elucidate the molecular mechanisms of AXL expression regulation. We constructed the AXL promoter reporter for monitoring its promoter activities. As a result, while the AXL promoter activity was inversely correlated with the AXL mRNA levels in both lung cancer cell lines and breast cancer cell lines as determined by reporter assays (Fig. 1a,b and Supplementary Fig. 1 ), the AXL mRNA levels were positively correlated with its 5′-UTR reporter activity ( Fig. 1c ) but not its 3′-UTR reporter activity in our recent study 32 . These results indicate that expression of AXL mRNA may be regulated by certain factors through its 5′-UTR. To identify the regions of the 5′-UTR potentially mediating the regulation of AXL mRNA, we discovered a possible destabilizing element in the AXL 5′-UTR and found that the polypyrimidine tract-binding protein 1 (PTBP1) was highly likely involved in this post-transcriptional regulation by using sequence alignment and RNA structure analysis ( Supplementary Fig. 2 ). PTBP1 regulates AXL mRNA expression. We performed the 5′-UTR reporter assay for monitoring AXL mRNA expression. The reporter constructs included that of the wild-type and those of various mutations in the 5′-UTR sequence. We found that deletion of the PTBP1 putative targeting site-2, but not site-1, from the AXL 5′-UTR recovered its reporter activity in CL1-0 and MDA-MB-231 cells ( Fig. 2a, Supplementary Fig. 3a ). We have observed an inverse correlation between endogenous levels of AXL and PTBP1 proteins when comparing the low invasive CL1-0 cells and the highly invasive CL1-5 and A549 cells. Similar results were obtained using other cancer cell types, including breast cancer cell lines MCF-7 and MDA-MB-231 ( Fig. 2b and Supplementary Fig. 3b ). Further, in addition to PTBP1, we also explored the possible regulation of AXL by the homologous PTBP2. As a result, we have further demonstrated that it is PTBP1, but not PTBP2, that could down-regulate AXL mRNA ( Fig. 2c ) and protein expression ( Fig. 2d ) in CL1-5 cells. As a further demonstration, we also examined the effects of knocking down the expression of PTBP1 by siRNA. As a result, up-regulation of AXL expression by PTBP1 siRNA was observed in other lung cancer cell lines, including A549 and H1299 ( Fig. 2d , and Supplementary  Fig. 3c ). These results indicate that PTBP1 may target site-2 sequence of the AXL 5′-UTR and result in destabilization of the AXL mRNA.
Binding of PTBP1 to AXL 5′-UTR in vitro and in vivo.
In light of the fact that AXL expression is indeed regulated by PTBP1, we would like to know whether the inhibition of AXL expression by PTBP1 is achieved through its physical interaction with the AXL′s mRNA 5′-UTR. If so, which parts of PTBP1 are involved. For this purpose, we constructed expression vectors for various normal variants and various mutants of PTBP1, Figure 1 . The AXL mRNA expression is correlated with AXL 5′-UTR reporter activity. (A) Inverse correlation between AXL mRNA level and AXL promoter reporter activity. CL1-0, CL1-3 and CL1-5 cells were transfected with the pGL3-AXL promoter luciferase construct, respectively. Luciferase reporter activity was assayed 48 h later. (B) The steady-state AXL mRNA levels of cell lines were compared by RT-PCR using GAPDH as an internal control. (C) AXL 5′-UTR reporter activity in CL1-0 and CL1-5 cells. The pMIR-Report-AXL 5′-UTR or p-MIR-Report (mock vector) plasmid was co-transfected with Renilla plasmid (serving as an internal control for transfection efficiency) into CL1-0 and CL1-5 cells. After 24 h, luciferase activity of the cell lysates was measured. Relative fold change in luciferase activity was plotted with respect to the pMIR-Report mock control. All reporter assays were performed in triplicate and the Renilla reporter activity was used to normalize the transfection efficiency. The error bars represent SD. *P < 0.05.
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(2019) 9:16922 | https://doi.org/10.1038/s41598-019-53097-2 www.nature.com/scientificreports www.nature.com/scientificreports/ PTBP1 regulates the stability of AXL mRNA. In this study, we have found that PTBP1 could regulate AXL mRNA expression ( Fig. 2c ), and its expression levels are inversely correlated with AXL mRNA levels ( Fig. 2b and Supplementary Fig. 3b ). To determine whether PTBP1 regulates AXL mRNA expression through affecting its transcription rates or via other post-transcriptional mechanisms, we performed the nuclear run-on assays. The differential expression of AXL mRNA in CL1-0 and CL1-5 cells is unlikely to result from altered transcription rates of the AXL gene, as examined by nuclear run-on assays with nuclei prepared from these cells. The transcription rates of AXL were neither affected by PTBP1 ( Fig. 4a and Supplementary Fig. 5a ). These results indicated that a post-transcriptional mechanism was involved. The AXL mRNA expression was down-regulated in the low invasive CL1-0 cells with low AXL than the highly invasive CL1-5 cells with high AXL levels ( Supplementary  Fig. 5b ). Additionally, to determine if the AXL mRNA stability is affected by PTBP1, we examined the half-life of AXL mRNA by employing the transcription inhibitor actinomycin D in CL1-0 and CL1-5 cells with or without ectopic over-expression of PTBP1. As a result, PTBP1 was found to down-regulate the stability of AXL mRNA (Fig. 4b,c ), suggesting that PTBP1 may act as a trans-acting factor regulating AXL mRNA stability.
PTBP1 suppresses cell viability and promotes apoptosis.
Next, we looked into the PTBP1's biological functions. MTT assay and colony formation assay were used to examine the effects of PTBP1 on cell growth and survival. The data show that over-expression of PTBP1 significantly attenuated cell growth and survival in CL1-0 and CL1-5 cells ( Fig. 5a,b ). In addition, while PTBP2 only slightly induced poly-ADP-ribose polymerase (PARP) cleavage, PTBP1 strongly increased PARP cleavage in both CL1-0 and CL1-5 cells (Fig. 5c ). Flow cytometric analysis was used to determine if the PTBP1-mediated apoptosis was affected by AXL. CL1-0 cells were first transfected with AXL construct, the next day, cells were transfected with PTBP1 expression vector. We found that over-expression of AXL may counteracted the PTBP1-mediated apoptosis ( Fig. 5d ) and decreased PTBP1-mediated PARP cleavage in CL1-0 and CL1-5 cells (Fig. 5e ). These results suggest that expression of AXL may attenuate PTBP1-induced apoptosis. www.nature.com/scientificreports www.nature.com/scientificreports/
PTBP1 regulates tumor growth in vivo.
To determine the effect of PTBP1 on lung tumor growth in vivo, we s.c. injected nude mice with stable transfectants of shPTBP1 or mock control vector. Data show that knockdown of PTBP1 expression significantly enhanced CL1-5 tumor growth ( Fig. 6a ). Representative images of tumors excised from each group were shown in Fig. 6b . In agreement with the tumor growth inhibition, the tumor weights were significantly increased when PTBP1 expression was knocked down (Fig. 6c ), demonstrating the tumor suppressive effect of PTBP1 in vivo.
Negative correlation between PTBP1 and AXL expression in lung cancer tissues.
To explore the possible clinical associations between PTBP1 and AXL, we made use of the Oncomine cancer profiling database and conducting lung tissue microarray analysis. Several lung cancer datasets, including GSE10245, GSE10072, GSE27262, and GSE8894, were analyzed and downloaded from Oncomine. The inverse correlation between expression levels of AXL and PTBP1 in normal vs. tumor (GSE10072: r = −0.60, P < 0.001; GSE27262: r = −0.63, P < 0.001) and normal vs. adenocarcinoma (ADC) (GSE10245: r = −0.40, P < 0.01; GSE8894: r = −0.34, P < 0.007) were observed as shown in Fig. 7a ,b, respectively. The Oncomine datasets used in this study and the associated probes information were shown in Supplementary Table 1 . Additionally, in our lung tissue microarray analysis, as shown in Supplementary Table 2, no significant differences were observed in the expression of AXL and PTBP1 (H-scores) among various clinicopathological variables examined (age, sex and pathological stage). However, AXL staining was greater in lung cancer tissues. The mean AXL score was higher in the lung cancer cohort than in the normal cohort (217.9 ± 37 vs 120.8 ± 29.9, P < 0.01) ( Fig. 7c ), whereas the mean PTBP1 H-score was lower in the lung cancer cohort than in the normal cohort (57.8 ± 17.8 vs 116.7 ± 22.4, P < 0.01) ( Fig. 7d ). PTBP1 was observed to be negatively correlated with AXL expression in lung cancer tissues (r = −0.7266, P < 0.01; Fig. 7e ). These data suggest that PTBP1 and AXL may be involved in lung cancer progression.
Discussion
AXL is associated with cancer invasion/progression, investigation of its gene regulation is of great importance, especially for its down regulation and/or inhibition in terms of clinical implications of counteracting cancer metastasis and reversing drug resistance. In this study, we have identified a molecular mechanism of AXL regulation by PTBP1 through controlling the AXL mRNA stability. We found that PTBP1, but not PTBP2, could down-regulate AXL mRNA by directly targeting its 5′-UTR. These findings may serve as an alternative way to attenuate AXL pathways as opposed to directly inhibit the AXL signaling, and may eventually help develop novel therapeutic approaches to avoid the development of cancer drug resistance and metastasis.
The splicing regulatory functions of PTBP1 have been previously correlated with malignant transformation [13] [14] [15] [16] . While PTBP1 could shuttle between the nucleus and cytoplasm, few reports investigated its roles in cytoplasm or its differential regulatory mechanisms and functions. CD154 (the CD40 ligand) plays a role in anti-tumor activity and growth inhibitory effects in breast cancer 33, 34 and recent studies indicate that PTBP1 may stabilize CD154 mRNA via targeting its 3′-UTR 21, 22 . Additionally, both our studies and others have shown that PTBP1 could down regulate AXL and HIF-1α expression in lung cancer cells via regulating their stability 25 , suggesting that PTBP1 may play roles as either a stabilizing or destabilizing factor in cytoplasm to mediate biological functions and affect cancer progression. Acting as a stabilizing or destabilizing factor may depend on the nature of the target sequences of mRNAs that PTBP1 binds and/or the cell context, i.e., involvement of other factors such as the RNA-binding protein HUR. It has previously been reported that HUR may work together with PTBP1 to regulate the translation of the HIF-1α 35 .
Recent studies indicate that overexpression of PTBP1 alone is not sufficient to cause transformation in normal cells. No significant changes in cell proliferation and anchorage-independent growth were observed in PTBP1-transfected WI-38 cells. PTBP1 overexpression alone does not stimulate cellular growth or induce a transformed phenotype in vitro 30 . In addition, several studies indicate that cAMP-dependent protein kinase (PKA) could phosphorylate several proteins, leading to apoptosis, cell growth arrest, and blockade of cancer cells motility and may function as a tumor suppressor [36] [37] [38] [39] [40] [41] . Several tumor suppressors are known PKA downstream effectors [42] [43] [44] . Interestingly, phosphorylation of PTBP1 at Ser16 by activated PKA may stimulate its accumulation in the cytoplasm 45 . Indeed studies have shown that cancer cells have an altered PTBP1 expression 27, 28 and the RNA splicing regulatory role of PTBP1 in the nucleus plays a role in promoting malignant phenotype in cancer cells 17, [29] [30] [31] . These findings indicate that PTBP1 may play different roles in the nucleus vs. cytoplasm, and hence, in normal vs. cancer cells by affecting its cellular localization. Additional supports for the hypothesis come from the fact that PTBP1 can up-regulate the tumor suppressor p27 and the Apaf-1 by binding and activating the IRES (internal ribosome entry site) of their mRNAs in cytoplasm 23, 24 . Therefore, the detailed regulatory mechanism of AXL modulated by PTBP1, especially the roles of PTBP1 in the cytoplasm vs. nucleus remains to be further clarified.
The PTBP1 could down regulate HIF-1α expression via regulating its mRNA stability and was able to inhibit cell invasion when localized in the cytoplasm 25 . PTBP1 could induce p19 mRNA expression via promoter regulation and inhibit cell proliferation 26 . Deletion of the RNA recognition motif 1 (RRM1) or RRM3 of PTBP1 abolished the interaction of PTBP1 and HIF-1α mRNA. On the other hand, deletion of the RRM3 was less effective in p19 expression and cell growth inhibition, although PTBP1 may regulate p19 induction through an indirect mechanism. These results suggest that RNA-binding activity of PTBP1 is crucial in p19 regulation. We www.nature.com/scientificreports www.nature.com/scientificreports/ have similarly found that PTBP1 lacking of RRM1 (PTBP1-D1) failed to bind 5′-UTR of AXL mRNA in vitro (Fig. 3b ). The RRM1 of PTBP1 is therefore crucial for this interaction in mediating biological functions and cancer progression.
The increased expression of PTBP1 may modulate pre-mature stop codon of PTBP2 resulting in nonsense-mediated mRNA decay 46 . In neuronal development, the post-transcriptional switch from PTBP1 to PTBP2 controls a widespread alternative splicing program and regulates neural precursor cell differentiation 31 . In our results, PTBP1 suppresses cell viability, promotes apoptosis (Figs. 5a, 5b and 5d ) and overexpression of PTBP1, but not PTBP2, could down-regulate AXL's mRNA ( Fig. 2c ) and protein expression ( Fig. 2d) . By contrast, while PTBP2 only slightly increased PARP cleavage, PTBP1 drastically induced PARP cleavage in both CL1-0 and CL1-5 cells (Fig. 5c ). Expression of AXL leads to activation of various downstream signaling pathways involved in proliferation, inhibition of apoptosis, and therapeutic resistance 47 . To clarify whether or not AXL is one of the main mediators of PTBP1-induced apoptosis, double transfection experiments were conducted. The results show that the PTBP1 may promote apoptosis in part through inhibition of AXL ( Figs. 5d and 5e ). In line with these results, overexpression of PTBP1 significantly decreased AXL expression and subsequently induced apoptosis via regulating AXL stability by targeting its mRNA 5′-UTR.
Targeting various receptor tyrosine kinases has been a focus in cancer therapy and related research. However, a major limitation of these approaches is that tumor cells eventually develop resistance and AXL activation is among the mechanisms of acquired resistance to EGFR inhibition in NSCLC treatment. In our previous studies, we have found that AXL not only is crucial in cancer cells invasiveness but also may play an important role in chemo-resistance. As an alternative to developing direct AXL inhibitors, we focus on elucidating AXL's regulatory mechanisms that may shed lights on counteracting its actions. There have been few reports on the relationship of PTBP1 and drug resistance. In studies on pancreatic cancers, PTBP1 has been shown to regulate the spicing of the pyruvate kinase (PKM) mRNA and thereby resulting in gemcitabine resistance 17 . Given that PTBP1 may destabilize AXL mRNA, it would be interesting to investigate, in cells expressing no or little PTBP1, whether AXL inhibitors may effectively inhibit cancer cells growth because of the potential likelihood of their AXL-dependency. In addition, in lung cancer cells acquiring resistance to gefitinib or erlotinib due to AXL, it is highly likely that up-regulation of PTBP1 would recover their drug sensitivity.
In this article, we clarify the molecular mechanism of AXL expression regulation by PTBP1 through controlling its mRNA stability via binding to the 5′-UTR. Indeed, over-expression of AXL may counteract the PTBP1-mediated apoptosis and knockdown of PTBP1 expression may increase tumor growth in vivo. In addition, PTBP1 expression was significantly higher in normal tissues and tumor-adjacent tissues compared to tumor tissues. Elucidation of the role of PTBP1 in the AXL-related malignant phenotypes may provide new molecular insights into the mechanisms underlying tumor progression and hopefully lead to new potential therapeutic modalities.
Methods
Cell culture and siRNA. The human breast cancer cell lines (MCF-7 and MDA-MB-231), human lung adenocarcinoma cell lines (CL1-0 and CL1-5), and the normal human lung fibroblasts (WI-38) were cultured in RPMI medium supplemented with 10% fetal bovine serum (Gibco BRL, Rockville, MD, USA), 2 μM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin, at 37 °C in a humidified incubator with 5% CO 2 . The siRNA sequence for PTBP1: 5′-CUGUGCCUAGCAAUAUU-3′ (MDBio).
Plasmids construction. The AXL promoter reporter and PTBP2 expression vector were constructed by insertion of the PCR-amplified sequences into the NheI/XhoI site of the pGL3 vector and EcoRI site of pcDNA3 vector, respectively. All PTBP1 variants were constructed by insertion of the PCR-amplified sequences into the BamHI/XhoI site of the pcDNA3 vector. The AXL 5′-UTR reporters were constructed in the pMIR-Report vector by inserting full-length and various mutation or deletion forms of the AXL 5′-UTR sequences into the BamHI restriction site of the pMIR-Report vector. Expression constructs of various RRM mutants of PTBP1 were as described previously 25 . All primers used for these constructs are listed in Supplemental Table 3 .
Luciferase reporter assays. Cells were transfected with a mixture of Lipofectamine 2000 (Invitrogen) and the firefly luciferase reporter plasmids pGL3-AXL promoter (−1726 ~ +1), pMIR-AXL 5′-UTR (full-length, wild-type), or various pMIR-AXL 5′-UTR mutations (deletions and putative PTBP1-binding sites mutations), along with pRL-SV40 (the Renilla luciferase transfection control). The cells were incubated for 24 h to allow Quantitative real-time RT-PCR. Total RNA were extracted from cells using Trizol according to the manufacturer's instruction. The first strand of cDNA was synthesized using the Superscript III kit (Invitrogen). PCR reactions were performed in a 20 μl reaction mixture containing 10 μM forward and reverse primers, 1X SYBER GREEN reaction mix (Takara). Actin served as an internal control for loading normalization. All reactions were performed in an ABI 7500 sequence detection system. The primer pairs for AXL were: 5′-CAGCGCAGCCTGCATGT-3′ (forward), 5′-TTGGCGTTATGGGCTTCG-3′ (reverse).
Nonradioactive nuclear run-on assay. The method was based on the incorporation of biotin-16-uridine-5′-triphosphate (biotin-16-UTP) (Sigma-Aldrich) into the nascent transcripts according to a modified protocol 48 . Total RNA was isolated with Trizol reagent (Invitrogen) and streptavidin beads (Qiagen) were used to isolate the biotin-labeled run-on RNA products. Real-time PCR and RT-PCR were performed as described above.
Determination of AXL mRNA Stability. CL1-0 and CL1-5 cells were first transfected with PTBP1 or control vector. 24 h later, actinomycin D (ActD) was added at 10 μg/ml and incubated for various periods. Total RNA was isolated and transcripts of AXL and Actin were analyzed by quantitative real-time RT-PCR. Lung cancer xenografts assay. All animal model experiments were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of National Health Research Institutes. Nude mice of 4 to 6 weeks old were used for in vivo tumor xenograft growth assay. A total of 1 × 10 6 CL1-5 cells stably overexpressing PTBP1 shRNA (or the mock vector control) suspended in 100 μl of PBS with equal volume of matrigel (BD Biosciences) were injected into the flanks of mice (n = 4), respectively. Tumor volumes were calculated using the following formula: Volume (mm 3 ) = width 2 × length. Tumors were monitored weekly and excised and weighed seven weeks after inoculation.
Expression correlation between AXL and PTBP1 in Oncomine datasets.
Several lung cancer datasets, including GSE10245, GSE10072, GSE27262, and GSE8894, were downloaded from Oncomine (http://www. oncomine.com). Information about the probes of genes of interest was downloaded from Oncomine and used in this study (Supplementary Table 1 ). For each dataset, gene expression data were downloaded entirely without selection. Since data from Oncomine have already been processed and normalized, they were used directly for Pearson correlation analysis.
Lung tissue microarray (TMA) and immunohistochemistry detection. Lung tissue microarrays were obtained from a commercial supplier (LC992, US Biomax, Inc, Rockville, MD, USA). The TMA (LC992) contained biospecimen from 33 patients consisting of 32 lung adenocarcinomas tissues, 34 tumor-adjacent non-tumor tissues (1.5 cm away from tumor), and 33 normal lung tissues, with single core per each case. Specific primary antibodies against AXL and PTBP1 (1:200; Santa Cruz Biotechnology) were used for IHC with a 2-step protocol. The tissue samples were formalin fixed, paraffin embedded. Tissue array sections were mounted on the positively charged SuperFrost Plus glass slide. The tissue microarray sections were cut at 5 μm in thickness. Individual cores were 1.0 mm in diameter and US Biomax supplied the following clinicopathologic characteristics of the subjects whose tissues were on the TMA: gender, age and grade. Samples were assessed in a blinded manner by one pathologist with no knowledge of the patients' clinicopathological data. The standard H-score (scale of 0-300) was calculated based on the staining intensity and percentage of stained cells.
Statistical analysis.
Quantitative PCR and reporter assays data are presented as mean ± SD. Differences between control and treatment groups were analyzed by Student's t-test. All experiments were performed in triplicate and repeated at least three times and P-values < 0.05 were considered statistically significant.
